ARCHIVES

Samuel Broder Plans To Leave Celera.

This article is from The Cancer Letter archive.

Vol. 36 No. 32 | September 10, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: Healy to Name Jay Moskowitz Deputy Direct, Promote Mahoney To Deputy Budge Director

March 6, 1992

NIH director; Targets Increases Favor Established Researchers

May 9, 1997

Top Management Shifts At Bristol-Myers Squibb Oncology, R&D Units

October 6, 1995

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

September 10, 1976

OSCC Groups Send Four Concepts To NCI Board

September 13, 1985

NCI Cooperative Group, Cancer Center Trials Listed

March 28, 2008